Law360, New York (February 05, 2013, 4:33 PM ET) -- A U.S. pharmaceutical industry group on Monday criticized the British Medical Journal's decision to publish only studies for which patient-level clinical trial data is made public, arguing it threatens patients' privacy and undermines the regulatory process.
The Pharmaceutical Research and Manufacturers of America denounced the BMJ policy in a statement targeting the recent book "Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients," by Dr. Ben Goldacre, which accuses the pharmaceutical industry of hiding unfavorable drug research and unduly influencing physicians.
"The demands by Dr....
Med Journal Rule Harms Patient Privacy, Pharma Group Says
To view the full article, take a free trial now.
